Eric A. Wright

Eric A. Wright

Auto-generated profile, based on publicly available information

Eric A. Wright

Geisinger – Department of Investigational Medicine, Department of Pharmacy, Geisinger College of Health Sciences, Scranton, PA, USA; Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2016 in Science
Verified
Journal Article
Closed access
PDF file
NANoura S. Abul-Husn
Noura S. Abul-Husn
KMKandamurugu Manickam
Kandamurugu Manickam
LJLaney Jones
Laney Jones
EWEric A. Wright
Eric A. Wright
DHDustin N. Hartzel
Dustin N. Hartzel
MMMichael F. Murray
Michael F. Murray
Unleashing the power of precision medicine: Precision medicine promises the ability to identify risks and treat patients on the basis of pathogenic genetic variation. Two studies combined exome sequencing results for over 50,000 people with their electronic health records. Dewey et al. found that ∼3.5% of individuals in their cohort had clinically actionable genetic variants. Many of these variants affected blood lipid levels that could influence cardiovascular health. Abul-Husn et al. extended these findings to investigate the genetics and treatment of familial hypercholesterolemia, a risk factor for cardiovascular disease, within their patient pool. Genetic screening helped identify at-risk patients who could benefit from increased treatment. Science , this issue p. 10.1126/science.aaf6814 , p. 10.1126/science.aaf7000

8 October 2015 in Journal of Medical Internet Research
Verified
Journal Article
Open access
EWEric Wright
Eric Wright
JDJonathan Darer
Jonathan Darer
XTXiaoqin Tang
Xiaoqin Tang
JTJason Thompson
Jason Thompson
LTLorraine Tusing
Lorraine Tusing
JWJan Walker
Jan Walker
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 March 2019 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
EWEric A. Wright
Eric A. Wright
JGJove H. Graham
Jove H. Graham
DMDaniel Maeng
Daniel Maeng
LTLorraine Tusing
Lorraine Tusing
LZLori Zaleski
Lori Zaleski
DPDean T. Parry
Dean T. Parry

1 August 2014 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
EWEric A. Wright
Eric A. Wright
BBBonnie Brown
Bonnie Brown
JGJacob Gettig
Jacob Gettig
JMJay L. Martello
Jay L. Martello
KMKatie S. McClendon
Katie S. McClendon
LBLynette R. Bradley-Baker
Lynette R. Bradley-Baker
Recommendations for the development and support of teaching and learning curriculum (TLC) experiences within postgraduate pharmacy training programs are discussed. Recent attention has turned toward meeting teaching- and learning-related educational outcomes through a programmatic process during the first or second year of postgraduate education. These programs are usually coordinated by schools and colleges of pharmacy and often referred to as "teaching certificate programs," though no national standards or regulation of these programs currently exists. In an effort to describe the landscape of these programs and to develop a framework for their basic design and content, the American Association of Colleges of Pharmacy Pharmacy Practice Section's Task Force on Student Engagement and Involvement, with input from the American Society of Health-System Pharmacists, reviewed evidence from the literature and conference proceedings and considered author experience and expertise over a two-year period. The members of the task force created and reached consensus on a policy statement and 12 recommendations to guide the development of best practices of TLC programs. The recommendations address topics such as the value of TLC programs, program content, teaching and learning experiences, feedback for participants, the development of a teaching portfolio, the provision of adequate resources for TLC programs, programmatic assessment and improvement, program transparency, and accreditation. TLC programs provide postgraduate participants with valuable knowledge and skills in teaching applicable to the practitioner and academician. Postgraduate programs should be transparent to candidates and seek to ensure the best experiences for participants through systematic program implementation and assessments.

3 October 2019 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TNTessa K. Novick
Tessa K. Novick
ASAditya Surapaneni
Aditya Surapaneni
JSJung-Im Shin
Jung-Im Shin
GAG. Caleb Alexander
G. Caleb Alexander
LILesley A. Inker
Lesley A. Inker
MGMorgan E. Grams
Morgan E. Grams
Background and objectives: Most opioids undergo kidney excretion. The goal of this study was to evaluate opioid-associated risks of death and hospitalization across the range of eGFR.Design, setting, participants, & measurements: The study population included adult primary care patients in Geisinger Health (Danville, PA) between 2008 and 2017. People receiving their first opioid prescription were propensity matched to people receiving NSAIDS (and, in sensitivity analysis, gabapentinoids) and the risk of death and hospitalization were compared, classifying opioid medication exposure as time-varying daily oral morphine milligram equivalents (MMEs) across time-varying eGFR.Results: The propensity-matched cohort included 46,246 patients prescribed either opioids or NSAIDs between 2008 and 2017 (mean [SD] age, 54 [16] years; 56% female; 3% of black race). Prescriptions for 1–59 and ≥60 MMEs were associated with higher risk of death (HR, 1.70; 95% CI, 1.41 to 2.05 for 1–59 MMEs; HR, 2.25; 95% CI, 1.82 to 2.79 for ≥60 MMEs) and hospitalization (HR, 1.38; 95% CI, 1.30 to 1.46 for 1–59 MMEs; HR, 1.68; 95% CI, 1.56 to 1.81 for ≥60 MMEs) compared with NSAID prescriptions, when evaluated at eGFR 80 ml/min per 1.73 m2. The relative risk of death associated with ≥60 MMEs was higher at lower GFR (e.g., eGFR, 40 ml/min per 1.73 m2; HR, 3.94; 95% CI, 2.70 to 5.75;Pfor interaction, 0.01). When gabapentinoids were used as the comparison medication, only ≥60 MMEs were significantly associated with higher risk of death (HR, 2.72; 95% CI, 1.71 to 4.34), although both 1–59 and ≥60 MMEs were associated with risk of hospitalization (HR, 1.22; 95% CI, 1.04 to 1.43 for 1–59 MMEs; HR, 1.54; 95% CI, 1.28 to 1.86 for ≥60 MMEs).Conclusions: The receipt of prescription opioids was associated with a higher risk of death and hospitalization compared with other pain medications, particularly with higher doses and at lower eGFR.

1 January 2020 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
MLMia E. Lussier
Mia E. Lussier
HEHaley J. Evans
Haley J. Evans
EWEric A. Wright
Eric A. Wright
MGMichael R. Gionfriddo
Michael R. Gionfriddo